Overview Dividends

(ALGN) Align Technology - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0162551016

Clear Aligners, Retainers, Intraoral Scanners, CAD/CAM Software

EPS (Earnings per Share)

EPS (Earnings per Share) of ALGN over the last years for every Quarter: "2020-09": 2.25, "2020-12": 2.61, "2021-03": 2.49, "2021-06": 3.04, "2021-09": 2.87, "2021-12": 2.83, "2022-03": 2.13, "2022-06": 2, "2022-09": 1.36, "2022-12": 1.73, "2023-03": 1.82, "2023-06": 2.22, "2023-09": 2.14, "2023-12": 2.42, "2024-03": 2.14, "2024-06": 2.41, "2024-09": 2.35, "2024-12": 2.44, "2025-03": 2.13, "2025-06": 2.49, "2025-09": 2.61,
EPS Growth (3y CAGR): 16.13%
EPS Trend (3y Corr): 78.1%
Last SUE: 1.67σ
Qual. Beats: 1

Revenue

Revenue of ALGN over the last years for every Quarter: 2020-09: 734.144, 2020-12: 834.52, 2021-03: 894.771, 2021-06: 1010.808, 2021-09: 1015.906, 2021-12: 1031.099, 2022-03: 973.219, 2022-06: 969.553, 2022-09: 890.348, 2022-12: 901.515, 2023-03: 943.147, 2023-06: 1002.173, 2023-09: 960.214, 2023-12: 956.726, 2024-03: 997.431, 2024-06: 1028.49, 2024-09: 977.872, 2024-12: 995.219, 2025-03: 979.262, 2025-06: 1012.449, 2025-09: 995.692,
Revenue Growth (3y CAGR): 3.68%
Revenue Trend (3y Corr): 64.9%
Last SUE: 0.56σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 42.0%
Value at Risk 5%th 62.2%
Relative Tail Risk -10.01%
Reward TTM
Sharpe Ratio -0.76
Alpha -55.00
Character TTM
Hurst Exponent 0.272
Beta 1.248
Beta Downside 0.766
Drawdowns 3y
Max DD 67.59%
Mean DD 33.35%
Median DD 35.40%

Description: ALGN Align Technology October 30, 2025

Align Technology (NASDAQ:ALGN) designs, manufactures, and markets the Invisalign clear-aligner system, Vivera retainers, and iTero intra-oral scanners, serving dental professionals in the United States, Switzerland, and other international markets.

The Clear Aligner segment bundles Invisalign treatments for adults, teens, and younger children (ages 6-10) through products such as Invisalign First, Invisalign Express, Lite, Moderate, and the Go line, plus ancillary tools like whitening kits, palatal expanders, and 3-D-printed orthodontic devices.

The Imaging Systems & CAD/CAM Services segment centers on the iTero scanner platform, paired with exocad design software, digital record-keeping tools, outcome simulators, and subscription-based services (e.g., pay-per-scan, scanner rentals) that support both orthodontic and restorative workflows.

Key metrics: FY 2024 revenue reached $4.9 billion, up ~13 % YoY, driven by a ~22 % increase in Invisalign case volume and a ~15 % rise in iTero scanner subscriptions. The global clear-aligner market is projected to grow at a 10-12 % CAGR through 2029, fueled by rising consumer preference for aesthetic, low-pain orthodontics and expanding dental insurance coverage for digital treatments.

For a deeper quantitative dive, the ValueRay platform offers a granular breakdown of ALGN’s valuation multiples and scenario analyses.

ALGN Stock Overview

Market Cap in USD 10,003m
Sub-Industry Health Care Supplies
IPO / Inception 2001-01-26
Return 12m vs S&P 500 -49.4%
Analyst Rating 4.0 of 5

ALGN Dividends

Currently no dividends paid

ALGN Growth Ratios

Metric Value
CAGR 3y -11.69%
CAGR/Max DD Calmar Ratio -0.17
CAGR/Mean DD Pain Ratio -0.35
Current Volume 1593.3k
Average Volume 1032.1k

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (378.4m TTM) > 0 and > 6% of Revenue (6% = 239.0m TTM)
FCFTA 0.09 (>2.0%) and ΔFCFTA 3.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 14.25% (prev 13.48%; Δ 0.78pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.11 (>3.0%) and CFO 656.1m > Net Income 378.4m (YES >=105%, WARN >=100%)
Net Debt (-917.3m) to EBITDA (745.3m) ratio: -1.23 <= 3.0 (WARN <= 3.5)
Current Ratio 1.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (72.4m) change vs 12m ago -3.13% (target <= -2.0% for YES)
Gross Margin 68.41% (prev 69.98%; Δ -1.58pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 63.22% (prev 62.21%; Δ 1.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 365.5 (EBITDA TTM 745.3m / Interest Expense TTM 1.56m) >= 6 (WARN >= 3)

Altman Z'' 3.62

(A) 0.09 = (Total Current Assets 2.53b - Total Current Liabilities 1.97b) / Total Assets 6.23b
(B) 0.39 = Retained Earnings (Balance) 2.42b / Total Assets 6.23b
(C) 0.09 = EBIT TTM 571.7m / Avg Total Assets 6.30b
(D) 1.09 = Book Value of Equity 2.48b / Total Liabilities 2.28b
Total Rating: 3.62 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 71.15

1. Piotroski 7.0pt = 2.0
2. FCF Yield 6.26% = 3.13
3. FCF Margin 14.23% = 3.56
4. Debt/Equity 0.02 = 2.50
5. Debt/Ebitda -1.23 = 2.50
6. ROIC - WACC (= -1.70)% = -2.12
7. RoE 9.75% = 0.81
8. Rev. Trend 64.93% = 4.87
9. EPS Trend 78.12% = 3.91

What is the price of ALGN shares?

As of November 19, 2025, the stock is trading at USD 132.28 with a total of 1,593,318 shares traded.
Over the past week, the price has changed by -8.45%, over one month by -1.96%, over three months by -8.73% and over the past year by -42.46%.

Is ALGN a buy, sell or hold?

Align Technology has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ALGN.
  • Strong Buy: 8
  • Buy: 3
  • Hold: 6
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the ALGN price?

Issuer Target Up/Down from current
Wallstreet Target Price 180.5 36.5%
Analysts Target Price 180.5 36.5%
ValueRay Target Price 112.8 -14.7%

ALGN Fundamental Data Overview November 17, 2025

Market Cap USD = 10.00b (10.00b USD * 1.0 USD.USD)
P/E Trailing = 26.5756
P/E Forward = 12.7877
P/S = 2.5118
P/B = 2.4862
P/EG = 0.8198
Beta = 1.868
Revenue TTM = 3.98b USD
EBIT TTM = 571.7m USD
EBITDA TTM = 745.3m USD
Long Term Debt = 121.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 31.1m USD (from shortTermDebt, last fiscal year)
Debt = 87.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -917.3m USD (from netDebt column, last quarter)
Enterprise Value = 9.06b USD (10.00b + Debt 87.3m - CCE 1.03b)
Interest Coverage Ratio = 365.5 (Ebit TTM 571.7m / Interest Expense TTM 1.56m)
FCF Yield = 6.26% (FCF TTM 566.6m / Enterprise Value 9.06b)
FCF Margin = 14.23% (FCF TTM 566.6m / Revenue TTM 3.98b)
Net Margin = 9.50% (Net Income TTM 378.4m / Revenue TTM 3.98b)
Gross Margin = 68.41% ((Revenue TTM 3.98b - Cost of Revenue TTM 1.26b) / Revenue TTM)
Gross Margin QoQ = 64.20% (prev 69.94%)
Tobins Q-Ratio = 1.45 (Enterprise Value 9.06b / Total Assets 6.23b)
Interest Expense / Debt = 1.79% (Interest Expense 1.56m / Debt 87.3m)
Taxrate = 40.09% (38.0m / 94.7m)
NOPAT = 342.5m (EBIT 571.7m * (1 - 40.09%))
Current Ratio = 1.29 (Total Current Assets 2.53b / Total Current Liabilities 1.97b)
Debt / Equity = 0.02 (Debt 87.3m / totalStockholderEquity, last quarter 3.96b)
Debt / EBITDA = -1.23 (Net Debt -917.3m / EBITDA 745.3m)
Debt / FCF = -1.62 (Net Debt -917.3m / FCF TTM 566.6m)
Total Stockholder Equity = 3.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.07% (Net Income 378.4m / Total Assets 6.23b)
RoE = 9.75% (Net Income TTM 378.4m / Total Stockholder Equity 3.88b)
RoCE = 14.29% (EBIT 571.7m / Capital Employed (Equity 3.88b + L.T.Debt 121.3m))
RoIC = 8.83% (NOPAT 342.5m / Invested Capital 3.88b)
WACC = 10.53% (E(10.00b)/V(10.09b) * Re(10.61%) + D(87.3m)/V(10.09b) * Rd(1.79%) * (1-Tc(0.40)))
Discount Rate = 10.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.26%
[DCF Debug] Terminal Value 71.81% ; FCFE base≈489.2m ; Y1≈558.4m ; Y5≈771.8m
Fair Price DCF = 122.5 (DCF Value 8.79b / Shares Outstanding 71.7m; 5y FCF grow 16.51% → 3.0% )
EPS Correlation: 78.12 | EPS CAGR: 16.13% | SUE: 1.67 | # QB: 1
Revenue Correlation: 64.93 | Revenue CAGR: 3.68% | SUE: 0.56 | # QB: 0

Additional Sources for ALGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle